Inhibition of JAK2 attenuates the increase in inflammatory markers in microglia from APP/PS1 mice

Neurobiology of Aging

Volumn 36, Issue 10, 2015, Pages 2716-2724

  Jones, Raasay S ^a   Minogue, Aedín M ^a   Fitzpatrick, Orla ^a   Lynch, Marina A ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

APP PS1; JAK2; M1 M2; Microglia; TG101209

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1; N TERT BUTYL 3 [5 METHYL 2 [4 (4 METHYL 1 PIPERAZINYL)PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; PRESENILIN 1; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; JAK2 PROTEIN, MOUSE; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

AGE; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN TISSUE; CELL CULTURE; CELL STIMULATION; CONTROLLED STUDY; DRUG TARGETING; ENZYME INHIBITION; GENE OVEREXPRESSION; MICROGLIA; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION; TRANSGENIC MOUSE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; METABOLISM; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CELLS, CULTURED; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; JANUS KINASE 2; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROGLIA; MOLECULAR TARGETED THERAPY; NITRIC OXIDE SYNTHASE TYPE II; PRESENILIN-1; PYRIMIDINES; SULFONAMIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84940955118     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2015.04.018     Document Type: Article

References (32)

1. Barrett J.P., Minogue A.M., Jones R.S., Ribeiro C., Kelly R.J., Lynch M.A. Bone marrow-derived macrophages from AbetaPP/PS1 mice are sensitized to the effects of inflammatory stimuli. J. Alzheimers Dis. 2015, 44:949-962.
2. Boehm U., Klamp T., Groot M., Howard J.C. Cellular responses to interferon-gamma. Annu. Rev. Immunol. 1997, 15:749-795.
3. Cherry J.D., Olschowka J.A., O'Banion M.K. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J. Neuroinflammation 2014, 11:98.
4. Chhor V., Le Charpentier T., Lebon S., Ore M.V., Celador I.L., Josserand J., Degos V., Jacotot E., Hagberg H., Savman K., Mallard C., Gressens P., Fleiss B. Characterization of phenotype markers and neuronotoxic potential of polarised primary microglia in vitro. Brain Behav. Immun. 2013, 32:70-85.
5. Colton C.A., Mott R.T., Sharpe H., Xu Q., Van Nostrand W.E., Vitek M.P. Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J. Neuroinflammation 2006, 3:27.
6. Colton C.A., Wilcock D.M. Assessing activation states in microglia. CNS Neurol. Disord. Drug Targets 2010, 9:174-191.
7. Combrinck M.I., Perry V.H., Cunningham C. Peripheral infection evokes exaggerated sickness behaviour in pre-clinical murine prion disease. Neuroscience 2002, 112:7-11.
8. Denieffe S., Kelly R.J., McDonald C., Lyons A., Lynch M.A. Classical activation of microglia in CD200-deficient mice is a consequence of blood brain barrier permeability and infiltration of peripheral cells. Brain Behav. Immun. 2013, 34:86-97.
9. Dungan L.S., McGuinness N.C., Boon L., Lynch M.A., Mills K.H. Innate IFN-gamma promotes development of experimental autoimmune encephalomyelitis: a role for NK cells and M1 macrophages. Eur. J. Immunol. 2014, 44:2903-2917.
10. El Khoury J., Toft M., Hickman S.E., Means T.K., Terada K., Geula C., Luster A.D. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med. 2007, 13:432-438.
11. Fiala M., Lin J., Ringman J., Kermani-Arab V., Tsao G., Patel A., Lossinsky A.S., Graves M.C., Gustavson A., Sayre J., Sofroni E., Suarez T., Chiappelli F., Bernard G. Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients. J. Alzheimers Dis. 2005, 7:221-232. discussion 255-262.
12. Gengler S., Hamilton A., Holscher C. Synaptic plasticity in the hippocampus of a APP/PS1 mouse model of Alzheimer's disease is impaired in old but not young mice. PLoS One 2010, 5:e9764.
13. Godbout J.P., Chen J., Abraham J., Richwine A.F., Berg B.M., Kelley K.W., Johnson R.W. Exaggerated neuroinflammation and sickness behavior in aged mice following activation of the peripheral innate immune system. FASEB J. 2005, 19:1329-1331.
14. Gordon S., Martinez F.O. Alternative activation of macrophages: mechanism and functions. Immunity 2010, 32:593-604.
15. Jankowsky J.L., Slunt H.H., Gonzales V., Savonenko A.V., Wen J.C., Jenkins N.A., Copeland N.G., Younkin L.H., Lester H.A., Younkin S.G., Borchelt D.R. Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. PLoS Med. 2005, 2:e355.
16. Jones R.S., Minogue A.M., Connor T.J., Lynch M.A. Amyloid-beta-induced astrocytic phagocytosis is mediated by CD36, CD47 and RAGE. J. Neuroimmune Pharmacol. 2013, 8:301-311.
17. Kelly R.J., Minogue A.M., Lyons A., Jones R.S., Browne T.C., Costello D.A., Denieffe S., O'Sullivan C., Connor T.J., Lynch M.A. Glial activation in A beta PP/PS1 mice is associated with infiltration of IFN gamma-producing cells. J. Alzheimers Dis. 2013, 37:63-75.
18. Kontzias A., Laurence A., Gadina M., O'Shea J.J. Kinase inhibitors in the treatment of immune-mediated disease. F1000 Med. Rep. 2012, 4:5.
19. Kotenko S.V., Pestka S. Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes. Oncogene 2000, 19:2557-2565.
20. Liu Y., Holdbrooks A.T., De Sarno P., Rowse A.L., Yanagisawa L.L., McFarland B.C., Harrington L.E., Raman C., Sabbaj S., Benveniste E.N., Qin H. Therapeutic efficacy of suppressing the Jak/STAT pathway in multiple models of experimental autoimmune encephalomyelitis. J. Immunol. 2014, 192:59-72.
21. Martinez F.O., Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014, 6:13.
22. McManus R.M., Higgins S.C., Mills K.H., Lynch M.A. Respiratory infection promotes T cell infiltration and amyloid-beta deposition in APP/PS1 mice. Neurobiol. Aging 2014, 35:109-121.
23. Meda L., Cassatella M.A., Szendrei G.I., Otvos L., Baron P., Villalba M., Ferrari D., Rossi F. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 1995, 374:647-650.
24. Michelucci A., Heurtaux T., Grandbarbe L., Morga E., Heuschling P. Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: effects of oligomeric and fibrillar amyloid-beta. J. Neuroimmunol. 2009, 210:3-12.
25. Minogue A.M., Jones R.S., Kelly R.J., McDonald C.L., Connor T.J., Lynch M.A. Age-associated dysregulation of microglial activation is coupled with enhanced blood-brain barrier permeability and pathology in APP/PS1 mice. Neurobiol. Aging 2014, 35:1442-1452.
26. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 2008, 22:23-30.
27. Perry V.H., Holmes C. Microglial priming in neurodegenerative disease. Nat. Rev. Neurol. 2014, 10:217-224.
28. Rezai-Zadeh K., Gate D., Gowing G., Town T. How to get from here to there: macrophage recruitment in Alzheimer's disease. Curr. Alzheimer Res. 2011, 8:156-163.
29. Stein M., Keshav S., Harris N., Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J. Exp. Med. 1992, 176:287-292.
30. Town T., Laouar Y., Pittenger C., Mori T., Szekely C.A., Tan J., Duman R.S., Flavell R.A. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat. Med. 2008, 14:681-687.
31. van Gool W.A., van de Beek D., Eikelenboom P. Systemic infection and delirium: when cytokines and acetylcholine collide. Lancet 2010, 375:773-775.
32. Verstovsek S., Kantarjian H.M., Estrov Z., Cortes J.E., Thomas D.A., Kadia T., Pierce S., Jabbour E., Borthakur G., Rumi E., Pungolino E., Morra E., Caramazza D., Cazzola M., Passamonti F. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 2012, 120:1202-1209.